Inventiva (IVA) EBITDA Margin (2020 - 2021)
Inventiva's (IVA) quarterly EBITDA Margin came in at 21021.54% in Q2 2021, down 904857.0% year-on-year from N/an in Q2 2020, and down 56.47% quarter-over-quarter from 13435.14% in Q1 2021.
Inventiva (IVA) EBITDA Margin (2020 - 2021) Analysis & Trends
Inventiva's EBITDA Margin history runs 2 years deep, the most recent figure standing at 21021.54% for Q2 2021.
- On a quarterly basis, EBITDA Margin fell 904857.0% year-over-year to 21021.54% in Q2 2021; TTM through Jun 2021 was 21339.07%, a N/A change from a year earlier, with the FY2025 full-year figure at 3145.51%, down 248297.0% from the prior year.
- EBITDA Margin declined to 21021.54% in Q2 2021 per IVA's latest filing, from 13435.14% in the prior quarter.
- Across five years, EBITDA Margin topped out at 7821.84% in Q1 2020 and bottomed at 21021.54% in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -21,021.54% |
| Mar 31, 2021 | -13,435.14% |
| Jun 30, 2020 | -11,972.97% |
| Mar 31, 2020 | -7,821.84% |